1. Compounds used to treat disorders or diseases caused by MDM2 and / or MDM4 activities, and compounds containing these compounds. Current compounds are used as antitumor agents. 1. Characteristic 1: compound (1) of formula or salt (2) selected from formula；B from a set of formulas (3)；Each R1 R1 is selected independently from halogen and methyl； R2 is selected from chlorine, fluorine, trifluoromethyl, methyl and cyanogen； R3 is selected from isopropyl, cyclopropene, isobutyl, cyclopentanediol and cyclopentanediol, or R3 is a residual formula (4),There, from Oh, oc832323,NH.8322；NHMe, NMe₂,Nhme and nhcoh； r83088 were selected from formula group (5)；R83099a is independently selected from oc832323；CH₂CH₃,OH, OCF₃ and H； R¹⁶ is selected from H, -O-C₁₋₄ alkyl,halo, OCF₃,CN -C (O) NR R-C (O) -morfolinil-4-ilo hidroxi-azetidin-1-il-carbonilo -CH NR R-CH NR -C (O) RCh8322； CN, methyl picolinate -,-CH C (O) NR R-Ch8322； (c) (o) oh - (o) oh -, CH 8322； C (o) o-tar c831832421；-N(R⁹)-C(O)-alquilo C₁₋₄,-NR⁹R¹⁰ and C₁₋₄ alkyl optionally substituted by 1 or 2 OH； R¹⁷ is selected from H, -O-C₁₋₄ alkyl,-CH C (O) NR R-CH₂C (O) O-C₁₋₄ alkyl,-CH C (O) OH -NR R-C (o) No. 8313； r83044,-CH₂NR⁹R¹⁰,-C (o) oc8323y-ch8322； CN； R 831222 was selected from h, - o-coking c833218331s 832424；Oh, ch8322283； nr8313； r183044；-No. 8313； r83044 and azetidin-1-ilo, replaced by Oh or two ch8323y and oh； r8313 was selected from h-o-aquilo c83318324；1. Lease of c83218331 and 83242431；-8313； 830404；-N(R⁹)-C(O)alquilo C₁₋₄ y -C(O)NR⁹R¹⁰；R83044 from h, ch8323y-ch8322； - ch832323；R2 1 was selected from - No. 83013； R1 830404；-CH₂NR⁹R¹⁰,C (o) nr8313； r83044 and CN； r83099 were selected from the following aspects: H, isoacrylonitrile-c (o) - (ch8322245)C₁₋₄- alkyl,said C₁₋₄ alkyl optionally substituted by 1 or 2 substituents independently selected from OH, = O, heterocyclyl¹-C₁₋₄- alkyl,wherein said heterocyclyl¹-C₁₋₄-alkyl is optionally substituted by 1 or 2 OH, and said heterocyclyl¹ may be optionally substit
